Trials / Completed
CompletedNCT01478269
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,927 (actual)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.
Conditions
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2011-11-23
- Last updated
- 2011-11-23
Locations
39 sites across 2 countries: Brazil, Italy
Source: ClinicalTrials.gov record NCT01478269. Inclusion in this directory is not an endorsement.